Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10158417 | Clinical Therapeutics | 2018 | 12 Pages |
Abstract
In clinical practice, the use of dulaglutide was relatively more limited in patients with a higher degree of renal impairment compared with use of insulin glargine. However, initiation of dulaglutide therapy, compared with insulin glargine therapy, was associated with a significantly smaller decrease in eGFR and a larger reduction in HbA1c during the 1 year postperiod.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Kristina S. PhD, Reema MBA, PhD, Jianmin PhD, Maureen J. PhD, Fady T. PhD, Brad MD,